Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 6/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.48 |
| ▸ | ITGAV | P06756 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7366599 | 0.89 | ITGB3 (0.41) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| SCHEMBL7168506 | 0.89 | ITGB3 (0.54) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| SCHEMBL7169150 | 0.85 | ITGB3 (0.46) | ITGB3ITGA2BITGAVUSP2GAA | |
| SCHEMBL7159785 | 0.85 | ITGB3 (0.42) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| SCHEMBL7160807 | 0.84 | ITGB3 (0.46) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| SCHEMBL13191086 | 0.84 | ITGB3 (0.46) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| SCHEMBL7163734 | 0.83 | ITGB3 (0.43) | ITGB3ITGA2BITGAVHSD17B10TP53 | |
| SCHEMBL7370460 | 0.83 | ITGB3 (0.43) | ITGB3ITGA2BITGAVHSD17B10TP53 | |
| SCHEMBL7165857 | 0.82 | MMP2 (0.47) | ITGB3ITGA2BUSP2GAAHSD17B10 | |
| SCHEMBL7163736 | 0.82 | TDP1 (0.53) | ITGB3ITGA2BUSP2GAAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6559144-B2 | Integrin inhibitors used to treat circulatory disorders, for thrombosis, myocardial infarct, coronary heart disease, arteriosclerosis, osteoporosis, pathological processes maintained or propagated by angiogenesis and tumor therapy | MERCK PATENT GESELLSCHAFT MIT (DE) | 2003-05-06 | — | — | US | disclosed |
| US-20010021709-A1 | Bicyclic amino acids | MERCK PATENT GESELLSCHAFT MIT BESCHRANKT PATENTS (DE) | 2001-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010021709-A1 | Bicyclic amino acids | ITGA1, ITGB1, ITGB2 | ITGB3 5/4885ITGA2B 14/4885ITGAV 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.